GlassScriptPhysician profile
Mark J Lobitz
NPI 1639141492
$1,704.35
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $258 · 2021: $463 · 2022: $476 · 2023: $187 · 2024: $45.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $333.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $207.74 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $207.29 | 2019-2022 | |
| Novo Nordisk INC | $130.92 | 2020-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $116.72 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $115.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.63 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $93.99 | 2019-2022 | |
| Lilly USA, LLC | $79.71 | 2022-2023 | Mounjaro |
| Inspire Medical Systems, INC. | $73.65 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $46.15 | 2020 | |
| Merck Sharp & Dohme LLC | $42.16 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.16 | 2022 | |
| Almatica Pharma LLC | $23.47 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.13 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $17.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.86 | 2022 | |
| Amarin Pharma, INC. | $14.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lobitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.